N/A
Completed N=166
Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation
Abortion · Dilation and Evacuation · hemorrhage · Blood Loss
Source: ClinicalTrials.gov NCT02083809 ↗
Enrolled (actual)
166
Serious AEs
1.3%
Results posted
Nov 2020
Primary outcomePrimary: Rate at Which Providers Intervene to Control Blood Loss During D&E Procedures. — 13; 6 Participants
Summary
Currently, there is very little research to identify ways to decrease blood loss during D&E (dilation and evacuation) procedures. The objective is to determine whether routine use of intravenous oxytocin will improve bleeding outcomes at the time of D&E at 18-24-weeks gestation. To evaluate the hypothesis, investigators will perform a randomized, double-blinded, placebo-controlled trial. The patient will be followed until discharged from the postoperative care unit during which time patient satisfaction, pain score and postoperative bleeding will be assessed.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate at Which Providers Intervene to Control Blood Loss During D&E Procedures. |
13; 6 | — |
Eligibility Criteria
Inclusion Criteria
- Requesting pregnancy termination
- Intrauterine pregnancy at 18- to 24-weeks gestation
- Gestational-age to be confirmed by ultrasound
- Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to 24-weeks gestation
- Willing and able to understand and sign written informed consents in English or Spanish and comply with study procedures
Exclusion Criteria
- Ultrasound findings suggestive of placenta accreta
- Patients requiring preoperative misoprostol
Data sourced from ClinicalTrials.gov (NCT02083809). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.